Alnylam Pharmaceuticals
ALNY
$0.00
-1.64%
Alnylam Pharmaceuticals is a biotechnology company that is a pioneer and leader in the development of RNA interference (RNAi) therapeutics, a platform for silencing disease-causing genes. The company operates in the competitive biopharmaceutical industry, with a portfolio of commercial products for rare diseases like hATTR amyloidosis, acute hepatic porphyria, and primary hyperoxaluria type 1, and has partnered programs in hypercholesterolemia and hemophilia. The current investor narrative is centered on the company's transition to sustainable profitability and the commercial execution of its growing product portfolio, as evidenced by its recent quarterly net income, while also weighing the long-term growth potential of its RNAi platform against the typical volatility and high valuation associated with innovative biotech firms.…
ALNY
Alnylam Pharmaceuticals
$0.00
Investment Opinion: Should I buy ALNY Today?
Rating: Hold. The core thesis is that Alnylam represents a compelling but high-risk turnaround story where strong fundamentals (profitability, growth) are currently overshadowed by severe technical damage and negative sentiment, warranting caution until the price stabilizes or shows signs of reversing the downtrend.
Supporting Evidence: The recommendation is anchored by the stock's 30.5% six-month decline and proximity to its 52-week low, indicating powerful selling pressure. Fundamentally, the bullish case is supported by an 84.95% YoY revenue surge, a forward P/E of 20.20x that is reasonable for the sector, and the generation of $465M in TTM free cash flow. However, these are counterbalanced by extreme quarterly earnings volatility, a high trailing P/E of 166.38x, and a short ratio of 4.89 signaling significant bearish bets.
Risks & Conditions: The two biggest risks are 1) a break below the $273 support triggering another leg down, and 2) a deceleration in revenue growth below 50% YoY, which would undermine the premium valuation narrative. This Hold would upgrade to a Buy if the stock establishes a firm base above $300 with improving volume, or if forward earnings estimates are revised materially higher. It would downgrade to a Sell on a confirmed break below $273 with high volume. Relative to its own history and biotech peers, the stock appears fairly valued on a forward basis but carries a high sentiment penalty.
Sign up to view all
ALNY 12-Month Price Forecast
Alnylam is a classic case of strong fundamentals colliding with broken technicals. The operational story—transition to profitability, robust cash flow, high growth—is compelling for long-term investors. However, the stock's severe underperformance and proximity to its lows cannot be ignored, suggesting the market is pricing in significant uncertainty or disappointment. The neutral stance reflects this dichotomy; the risk/reward is balanced at current levels. The stance would turn bullish on a confirmed technical reversal above $300 with strong volume, signaling institutional accumulation. It would turn bearish on a breakdown below $273, which would likely lead to a swift move towards $250.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Alnylam Pharmaceuticals's 12-month outlook, with a consensus price target around $0.00 and implied upside of — versus the current price.
Average Target
$0.00
10 analysts
Implied Upside
—
vs. current price
Analyst Count
10
covering this stock
Price Range
$0 - $0
Analyst target range
The stock is covered by a modest number of analysts, with 10 firms providing estimates, indicating it is a well-followed but not overwhelmingly covered mid-cap biotech. The consensus sentiment appears bullish, as evidenced by recent institutional ratings which include multiple 'Buy' reiterations from firms like HC Wainwright, Chardan Capital, and Needham in early 2026, though one notable downgrade from Jefferies from 'Buy' to 'Hold' in March 2026 introduces a note of caution. Analyst revenue estimates for the coming period average $11.74 billion, with a wide range from a low of $11.10 billion to a high of $13.71 billion, reflecting significant uncertainty or variability in sales projections for its commercial portfolio and pipeline catalysts. The wide target range, coupled with the stock's significant price decline, suggests high uncertainty about the near-term trajectory, but the preponderance of 'Buy' ratings implies analyst confidence in the company's fundamental turnaround and long-term platform value outweighs near-term volatility concerns.
Bulls vs Bears: ALNY Investment Factors
The bull case, grounded in explosive 85% revenue growth and a definitive turn to profitability, is fundamentally strong but is currently being overwhelmed by severe technical damage and negative market sentiment. The bear side holds stronger near-term evidence, as the stock's 30%+ decline and proximity to 52-week lows demonstrate a clear breakdown in investor confidence. The single most important tension in the investment debate is whether the company's operational inflection (profitability, strong cash flow) can regain credibility with the market fast enough to prevent a technical breakdown below the $273 support level. The resolution of this sentiment vs. fundamentals disconnect will dictate the stock's direction.
Bullish
- Exceptional Revenue Growth: Q4 2025 revenue grew 84.95% year-over-year to $1.10 billion, driven by strong commercial execution of RNAi therapeutics like GIVLAARI ($160.67M) and ONPATTRO ($70.76M). This acceleration demonstrates robust product uptake and validates the commercial platform.
- The company swung to a net profit of $186.42 million in Q4 2025 from a loss of $83.76 million a year ago, with a trailing net margin of 8.45%. This transition to sustainable profitability is a critical milestone for a growth-stage biotech.
- Strong Gross Margins & Cash Flow: Gross margin stands at a robust 81.77%, indicating significant pricing power for its innovative therapies. The company generated $465.38 million in trailing twelve-month free cash flow, providing ample liquidity for R&D and operations.
- Analyst Bullishness Amid Weakness: Despite the stock's 30.5% six-month decline, analyst sentiment remains predominantly bullish with multiple 'Buy' reiterations in early 2026. This suggests professional confidence in the long-term thesis outweighs near-term price volatility.
Bearish
- Severe Technical Downtrend: The stock is down 30.52% over six months and trades at $278.09, perilously close to its 52-week low of $273.11. This persistent negative momentum, with a -35.95% relative strength vs. the market, reflects deep investor pessimism.
- Extreme Earnings Volatility: Quarterly net income has swung from a $251.08 million profit in Q3 2025 to a $66.28 million loss in Q2 2025. This lumpiness, common in biotech due to milestone timing, creates significant uncertainty for investors and complicates valuation.
- High Trailing Valuation: A trailing P/E of 166.38x is exceptionally high, even for a growth biotech, indicating the stock price embeds near-perfect execution of future earnings growth. Any stumble could lead to severe multiple compression.
- Leveraged Balance Sheet: A debt-to-equity ratio of 1.62 indicates a leveraged capital structure. While manageable with current cash flow, it increases financial risk if revenue growth decelerates or R&D costs escalate unexpectedly.
ALNY Technical Analysis
The stock is in a pronounced downtrend, having declined 30.52% over the past six months and 10.96% over the past year, significantly underperforming the broader market which is up 24.99% over the same one-year period. With a current price of $278.09, the stock is trading near the bottom of its 52-week range, at approximately 56% of the distance from its 52-week low of $273.11 to its high of $495.55, indicating it is in a deeply oversold territory that may present a value opportunity but also reflects substantial negative momentum and investor pessimism. Recent momentum remains negative, with the stock down 5.51% over the past month and 10.92% over the past three months, confirming the continuation of the longer-term downtrend; this persistent weakness is further highlighted by a beta of 0.267, suggesting the stock has been significantly less volatile than the market but has failed to participate in the market's rally, exhibiting severe relative weakness. Key technical support is clearly defined at the 52-week low of $273.11, with resistance far above at the 52-week high of $495.55; a decisive break below the $273 support level could trigger another leg down, while any meaningful recovery would need to overcome significant overhead supply, and the low beta indicates the stock's price action is currently driven more by idiosyncratic company factors than broad market movements.
Beta
0.27
0.27x market volatility
Max Drawdown
-43.4%
Largest decline past year
52-Week Range
$273-$496
Price range past year
Annual Return
-11.0%
Cumulative gain past year
| Period | ALNY Return | S&P 500 |
|---|---|---|
| 1m | -5.5% | +0.1% |
| 3m | -10.9% | +13.9% |
| 6m | -30.5% | +8.5% |
| 1y | -11.0% | +25.6% |
| ytd | -30.5% | +9.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ALNY Fundamental Analysis
Revenue growth has been exceptionally strong, with the most recent quarterly revenue of $1.10 billion representing an 84.95% year-over-year increase, a significant acceleration from the $593 million reported in the year-ago quarter. The growth is primarily driven by the company's commercial products, with GIVLAARI contributing $160.67 million and ONPATTRO $70.76 million in the latest period, indicating a robust commercial launch trajectory for its RNAi therapeutics. The company has achieved a notable inflection towards profitability, reporting net income of $186.42 million for Q4 2025 compared to a net loss of $83.76 million in the prior-year quarter, with a trailing twelve-month net margin of 8.45% and a gross margin of 81.77% demonstrating strong pricing power and scalability. Profitability has improved dramatically, as evidenced by the swing from negative to positive net income and an operating margin of 13.51% in the latest quarter, although quarterly results show some volatility with net income ranging from a loss of $66.28 million in Q2 2025 to a profit of $251.08 million in Q3 2025, reflecting the lumpy nature of biotech earnings due to milestone payments and R&D timing. The balance sheet shows a debt-to-equity ratio of 1.62, indicating a leveraged but manageable capital structure, while the company generated substantial free cash flow of $465.38 million over the trailing twelve months and holds a strong current ratio of 2.76, providing ample liquidity to fund ongoing R&D and commercial operations without immediate external financing needs.
Quarterly Revenue
$1.1B
2025-12
Revenue YoY Growth
+0.84%
YoY Comparison
Gross Margin
+0.75%
Latest Quarter
Free Cash Flow
$465383000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ALNY Overvalued?
Given the company's positive net income of $186.42 million in the latest quarter, the primary valuation metric selected is the Price-to-Earnings (P/E) ratio. The trailing P/E ratio is exceptionally high at 166.38x, while the forward P/E is significantly lower at 20.20x, indicating the market is pricing in a substantial acceleration in earnings growth over the next year, likely driven by expectations of sustained profitability from its commercial products. Compared to the broader biotechnology sector, which typically trades at a forward P/E in the mid-20s to 30s, Alnylam's forward P/E of 20.20x appears to be at a discount or in line, suggesting the market is not ascribing a significant premium for its platform leadership despite its recent profitability milestone and high gross margins of over 80%. Historically, the stock's own valuation has been volatile, with its trailing P/E ratio ranging from negative figures during loss-making periods to 70.52x as of the end of 2025; the current trailing P/E of 166.38x is near the upper end of its recent historical range, reflecting the market's attempt to value the company on earnings after years of losses, but also signaling that expectations embedded in the price are high and leave little room for execution missteps.
PE
166.4x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -456x~71x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
81.9x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Alnylam's primary financial risk is earnings volatility, as evidenced by quarterly net income swinging from a $251M profit to a $66M loss within recent quarters, driven by the lumpy nature of milestone payments and R&D timing. This makes consistent quarterly forecasting difficult. While the debt-to-equity of 1.62 is manageable, it introduces leverage risk if the commercial ramp slows. Furthermore, the company's valuation is highly sensitive to growth continuation; a deceleration from the current 85% YoY pace could trigger a severe derating from its lofty trailing P/E of 166x.
Market & Competitive Risks: The stock faces acute valuation compression risk, trading near its 52-week low after a 30.5% six-month decline, which suggests the market is already pricing in significant pessimism. Its low beta of 0.267 indicates it has not participated in the market rally, showing it is driven by idiosyncratic factors, likely concerns over commercial execution or pipeline competition. The wide range in analyst revenue estimates ($11.1B to $13.7B) underscores high uncertainty about future sales, leaving the stock vulnerable to misses versus elevated expectations.
Worst-Case Scenario: The worst-case scenario involves a breakdown of the $273.11 support level following a Q2 2026 earnings miss or guidance reduction, confirming fears of commercial deceleration. This could trigger a cascade of analyst downgrades (following Jefferies' recent Hold rating) and force leveraged longs to exit, mirroring the stock's historical max drawdown of -43.39%. A realistic downside target in this adverse scenario would be a re-test of the 52-week low, implying a potential loss of approximately -2% from the current price of $278.09, with further downside to the $250 range (-10%) if sentiment deteriorates severely.
FAQ
The key risks are, in order of severity: 1) Sentiment & Technical Risk: The stock is in a severe downtrend, down 30.5% in six months, and a break below $273 support could lead to further sharp declines. 2) Earnings Volatility Risk: Quarterly results are highly lumpy (e.g., $251M profit to $66M loss), creating uncertainty and potential for earnings misses. 3) Valuation Compression Risk: The high trailing P/E of 166x leaves no room for error; any growth slowdown could trigger a severe multiple contraction. 4) Financial Leverage Risk: A debt-to-equity ratio of 1.62, while manageable, increases risk if the operating environment deteriorates.
The 12-month forecast is bifurcated, with a 50% probability Base Case target of $300-$350, a 30% probability Bull Case target of $400-$495, and a 20% probability Bear Case target of $250-$273. The Base Case is most likely, assuming the company meets consensus revenue estimates of ~$11.74B and the forward P/E multiple holds around 20-25x as profitability becomes more consistent. The key assumption is that the stock stabilizes and begins to recover as quarterly earnings volatility decreases and investor confidence in the commercial story rebuilds.
The answer depends on the timeframe. On a trailing basis, with a P/E of 166.38x, the stock is clearly overvalued, pricing in several years of perfect earnings growth. On a forward basis, the P/E of 20.20x is in line with or at a discount to the biotech sector, suggesting fair value or slight undervaluation relative to future earnings potential. Compared to its own history, trading at 56% of its 52-week high, the stock is deeply discounted on a price basis. The market is currently valuing ALNY as a profitable commercial-stage biotech, not a speculative platform, but remains skeptical about growth sustainability.
ALNY presents a high-risk, high-potential-reward opportunity. For investors with a long-term horizon (3+ years) and high risk tolerance, the current price near 52-week lows could be an attractive entry point, given the company's 85% revenue growth and shift to profitability. The forward P/E of 20.20x is not excessive for the biotech sector. However, it is not a good buy for short-term traders or risk-averse investors, given the severe downtrend, high short interest (ratio 4.89), and earnings volatility. The biggest near-term risk is a break below the $273 support level.
ALNY is suitable only for long-term investment with a minimum holding period of 3-5 years. The stock's low beta (0.267) and high idiosyncratic volatility make it a poor short-term trading vehicle, as its price is driven by company-specific clinical and commercial news, not broad market moves. Furthermore, the investment thesis is based on the long-term value of the RNAi platform and sustained commercial execution, which will take years to fully unfold. The lack of a dividend also makes it purely a capital appreciation story, aligning with a long-term growth portfolio allocation.
